216 related articles for article (PubMed ID: 15038405)
1. Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
Wien Klin Wochenschr; 2004 Feb; 116(4):135-9. PubMed ID: 15038405
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
3. MMP-1 and MMP-2 expression in uterine leiomyosarcoma and correlation with different clinicopathologic parameters.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2003 Oct; 10(7):443-6. PubMed ID: 14519487
[TBL] [Abstract][Full Text] [Related]
4. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029
[TBL] [Abstract][Full Text] [Related]
5. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
6. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
7. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
[TBL] [Abstract][Full Text] [Related]
8. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis.
D'Angelo E; Espinosa I; Ali R; Gilks CB; Rijn Mv; Lee CH; Prat J
Gynecol Oncol; 2011 May; 121(2):328-33. PubMed ID: 21316747
[TBL] [Abstract][Full Text] [Related]
9. Leiomyosarcoma: One disease or distinct biologic entities based on site of origin?
Worhunsky DJ; Gupta M; Gholami S; Tran TB; Ganjoo KN; van de Rijn M; Visser BC; Norton JA; Poultsides GA
J Surg Oncol; 2015 Jun; 111(7):808-12. PubMed ID: 25920434
[TBL] [Abstract][Full Text] [Related]
10. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
11. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
[TBL] [Abstract][Full Text] [Related]
12. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
Anticancer Res; 2003; 23(1B):729-32. PubMed ID: 12680175
[TBL] [Abstract][Full Text] [Related]
13. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
14. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases.
Mayerhofer K; Obermair A; Windbichler G; Petru E; Kaider A; Hefler L; Czerwenka K; Leodolter S; Kainz C
Gynecol Oncol; 1999 Aug; 74(2):196-201. PubMed ID: 10419731
[TBL] [Abstract][Full Text] [Related]
15. Myxoid Leiomyosarcoma of the Uterus: A Clinicopathologic Analysis of 30 Cases and Review of the Literature With Reappraisal of Its Distinction From Other Uterine Myxoid Mesenchymal Neoplasms.
Parra-Herran C; Schoolmeester JK; Yuan L; Dal Cin P; Fletcher CD; Quade BJ; Nucci MR
Am J Surg Pathol; 2016 Mar; 40(3):285-301. PubMed ID: 26866354
[TBL] [Abstract][Full Text] [Related]
16. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma.
Loizzi V; Cormio G; Nestola D; Falagario M; Surgo A; Camporeale A; Putignano G; Selvaggi L
Oncology; 2011; 81(2):91-7. PubMed ID: 21968290
[TBL] [Abstract][Full Text] [Related]
18. Leiomyosarcoma of the uterus: a clinicopathologic study of 21 cases.
Hsieh CH; Lin H; Huang CC; Huang EY; Chang SY; ChangChien CC
Acta Obstet Gynecol Scand; 2003 Jan; 82(1):74-81. PubMed ID: 12580845
[TBL] [Abstract][Full Text] [Related]
19.
de Almeida BC; Dos Anjos LG; Uno M; Cunha IWD; Soares FA; Baiocchi G; Baracat EC; Carvalho KC
Cells; 2019 Nov; 8(11):. PubMed ID: 31744257
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus.
Zhai YL; Nikaido T; Toki T; Shiozawa A; Orii A; Fujii S
Br J Cancer; 1999 Jul; 80(10):1658-64. PubMed ID: 10408415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
